Retinoids, vitamin A and its natural and synthetic derivatives, regulate a wide spectrum of biological processes including cellular proliferation, differentiation, and development. 1) They have been recognized as promising agents for chemoprevention and chemotherapy for a variety of human cancers including colon cancer. [1] [2] [3] [4] The biological and pharmacological effects of retinoids are mainly mediated through two classes of nuclear receptors, retinoic acid receptors (RARs) and retinoid X receptors (RXRs), which belong to the steroid/thyroid hormone receptor superfamily. 5, 6) RARs contribute to dynamic remodeling of local chromatin structure at the level of target genes containing retinoic acidresponsive elements (RAREs) by recruiting coactivator or corepressor complexes with histone acetyltransferase (HAT) activity or histone deacetylase (HDAC), respectively, and thereby regulate gene expression. 7, 8) Among multiple isoforms of retinoid receptors, i.e., RARa, b, and g, and RXRa, b, and g, RARb is primarily expressed in epithelial cells, suggesting that RARb may be involved in maintaining normal homeostasis of epithelia.
In our previous study, we showed that autoregulation of RARb gene expression plays an important role in the response of colon cancer cells to all-trans-retinoic acid (RA) and that loss of RA sensitivity in RARb induction is a common feature of human colon cancer cells. 9) Since RARb have been proposed to be responsible for a significant part of the antiproliferative action of RA, identification of factors that inhibit activation of the RARb promoter could provide a better understanding of the growth control and transformation processes of colonic epithelia. Among the many factors potentially involved, alterations affecting either the RARb promoter or regulatory transacting factors may be crucial to down-regulate RARb activity.
In the present investigation, we studied possible defects associated with the abnormal regulation of the RARb gene in a RA-resistant human colon cancer cell line, DLD-1. Here, we report that overexpression of coactivators of nuclear receptors, CBP/p300, and treatment with the HDAC inhibitor, trichostatin A (TSA), enhanced bRARE activity in DLD-1 cells, which indicates that coactivators/corepressors may be a factor determining RA sensitivity in colon cancer cells.
MATERIALS AND METHODS

Cell Lines and Culture
The human colon cancer cell lines DLD-1 (ATCC CCL 221) and HCT-15 (ATCC CCL 225) were obtained from the American Type Culture Collection and maintained in minimal essential medium (MEM) containing 10% fetal bovine serum. All-trans-RA and TSA were purchased from Sigma Chemical (St. Louis, MO, U.S.A.). The other chemicals used were of the purest grade available from Sigma.
Plasmids The expression plasmids pRc/RSV-CBP, pCDNA3.1-p300, pCR3.1-hSRC-1, and pCDNA3.1-NCoR have been described previously. 10, 11) The reporter constructs, RARb promoter (BglII-BamHI)-tk-CAT, and the bRARELuc, bRARE linked to the heterologous thymidine kinase promoter, have been described previously. 10, 12) The luciferase reporter constructs encoding various fragments of the RARb promoter, i.e., 9, 12) Luciferase activity was determined and normalized for transfection efficiency by the corresponding b-gal activity. When the cells were treated with TSA, luciferase activity was normalized by the corresponding protein content since the expression of b-gal was enhanced by TSA treatment. For statistical analysis, one-way analysis of variance was performed using Graphpad Instat ® (GraphPad Software). A value of pϽ0.05 was considered statistically significant.
Western Blot Analysis Cells were lysed in a lysis buffer containing 50 mM Tris (pH 7.5), 150 mM NaCl, 10% NP-40, 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 mg/ml leupeptin, 10 mg/ml aprotinin, and 10 mg/ml pepstatin. Thirty micrograms of protein from whole-cell lysate were subjected to 8% sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to a nitrocellulose membrane (Amersham Pharmacia Biotech, Buckinghamshire, U.K.), and identified with specific antibodies against anti-CBP (Santa Cruz Biotech., Santa Cruz, CA, U.S.A.), anti-NCoR (Santa Cruz Biotech.), anti-Sin3A (Santa Cruz Biotech.), and anti-a-tubulin (Oncogene, Boston, MA, U.S.A.) antibodies. The protein concentration was quantified by a bicinchoninic acid assay (Pierce, Rockford, IL, U.S.A.).
RESULTS
Transcriptional Activity of RARb b Gene Promoter in Human Colon Cancer Cells
In our previous report, we showed that autoregulation of RARb gene expression plays an important role in the response of colon cancer cells to alltrans-RA and that loss of RA sensitivity of RARb induction is a common feature of human colon cancer cells.
9) The insensitivity of RARb gene induction by RA may represent the overall impairment of RA response in colon cancer cells, which may be associated with the development and progression of neoplastic disease. In the present investigation, we studied possible defects associated with the abnormal regulation of the RARb gene in an RA-resistant human colon cancer cell line, DLD-1. First, we examined the transcriptional activity of the proximal regulatory region of the RARb gene promoter in the colon cancer cells. We constructed a reporter gene in which the BglII-BamHI fragment of the RARb gene promoter was linked to the luciferase gene as shown in Fig.  1A . The resulting construct was transiently transfected into both RA-sensitive HCT-15 cells and RA-resistant DLD-1 cells. In HCT-15, a 4.5-fold induction of luciferase activity was observed in the presence of RA. However, the induction in DLD-1 was lower at 2.8-fold, which agrees well with the previous results of the induction of RARb transcription fol- lowing all-trans-RA treatment (Fig. 1B) . 9) To localize regions that are possibly responsible for the differences in the RA response in these two cell lines, the reporter constructs containing truncated RARb promoter fragments linked to the luciferase gene were tested for their response to RA (Fig. 1A) . As shown in Fig. 1B , both reporters responded to RA treatment in a manner similar to the BglIIBamHI-Luc and bRARE-Luc. The results may indicate that the loss of RA response in the induction of endogenous RARb gene in DLD-1 cells is not likely due to the presence of specific cis-elements. Further, we confirmed this observation by sequencing the region of the RARb promoter cloned from DLD-1, which did not show any alterations (data not shown). Thus the results show that a general defect in the common factor(s) regulating the activity of the RARb promoter may be involved in RA sensitivity and imply that the factor(s) is missing or defective in DLD-1.
Coexpression of CBP/p300 Induced Transcriptional Activity of b bRARE in DLD-1 but Not in HCT-15 Coactivators previously implicated in ligand-dependent activation functions of retinoid receptors include CREB-binding protein (CBP) and p300, and the steroid receptor coactivator-1 (SRC-1)-related family of proteins. 7, 8, 14) The retinoid-resistant cells may have abnormal expressions or functions of coactivators and/or corepressors that are specifically associated with the transcription of RARb. Therefore we tested whether enforced expression of the auxiliary factors affected the inducibility of the RARb gene. As shown in Fig. 2A , cotransfection of increasing amounts of the CBP expression vector up-regulated RARb promoter activity in DLD-1 cells in a dose-dependent manner, whereas cotransfection of CBP in HCT-15 did not enhance the bRARE activity. At the highest amount of CBP tested, i.e., 500 ng, the induction of bRARE activity was as good as that in HCT-15. Similar results were observed when p300 was cotransfected (Fig. 2B) . bRARE activity was not increased when SRC-1 was cotransfected into DLD-1 but it was further enhanced in HCT-15 (Fig. 2C) . The results suggest that CBP/p300 might be important regulators of the induction of the RARb gene in colon cancer cells. When NCoR was cotransfected with the bRARE reporter into HCT-15 cells, the RA response was abolished (Fig. 3) . The results indicate that corepressors are also associated with RA sensitivity in colon cancer cells. Next we measured the expression level of the coactivators and corepressors in the colon cancer cells. As shown in Fig.  4 , the expression level of CBP protein was higher in HCT-15, while that of NCoR and Sin3A was higher in DLD-1. The results suggested that the differential expression of the coacti- vators/corepressors may be important determinants of RA sensitivity in colon cancer cells.
TSA Enhances Transcriptional Activity of b bRARE in DLD-1 Retinoid receptors are known to induce local chromatin changes at the level of target genes containing bRARE by recruiting multiprotein complexes containing coactivators or corepressors with HAT and HDAC activity, which dynamically modulate chromatin structure and thereby regulate gene expression. 7, 8, 14) Recently, a specific HDAC inhibitor, trichostatin A (TSA), was reported to affect the chromatin state of the RARb promoter, resulting in restoration of RAinduced RARb transcription in RA-resistant breast cancer cells. 15) We examined whether TSA enhances the bRARE activity in DLD-1 cells, since a corepressor such as NCoR was likely associated with RARb transcription in colon cancer cells (Figs. 3, 4) . As shown in Fig. 5 , both basal and RA-induced bRARE activities were increased significantly when TSA was added to the culture medium. The increases were TSA dose dependent. The effect of TSA on the activities of the reporter without the bRARE sequence was shown as a control. The results indicate that HDAC activity may participate in the regulation of RARb activity in colon cancer cells.
DISCUSSION
The expression of the RARb gene is autoregulated in response to all-trans-RA, since a strong RA response element, bRARE, is present in the proximal regulatory region of RARb gene. 16, 17) We previously reported that the autoregulation of RARb gene expression plays an important role in the response of colon cancer cells to all-trans-RA and that loss of RA sensitivity is a general feature of human colon cancer cells. 9) Since RARb is responsible for a significant part of the antiproliferative action of RA, identification of factors that inhibit activation of the RARb promoter could provide a better understanding of the growth control and transformation process of colonic epithelia. In the present investigation, we report that coactivators and corepressors such as CBP/p300 and NCoR, respectively, are important factors determining RA sensitivity in RARb gene expression in colon cancer cells.
CBP and its homologue p300 are large nuclear molecules that coordinate a variety of transcriptional pathways with potent HAT activity which link transcription to chromatin remodeling. 18, 19) Recent evidence showed that transcription of the RARb promoter is also mediated by RARs by recruiting CBP/p300 with HAT activity. 7, 8) As expected, both CBP and p300 are required for some RA-dependent responses, such as apoptosis and complete arrest in the G1 phase of the cell cycle. 20) In the present study, we showed that cotransfection of CBP/p300 into an RA-resistant colon cancer cell line, DLD-1, enhanced the transcriptional activity of bRARE as much as that observed in an RA-sensitive HCT-15 (Fig. 2) . We further demonstrated that the expression of CBP was higher in HCT-15, while it was significantly lower in DLD-1. The results suggest that the abnormal expression of CBP may impair RA/RAR signaling pathways in DLD-1 cells. Many reports have addressed the potential involvement of CBP/p300 in neoplastic diseases in humans. Alterations of the human CBP gene have been implicated in hematologic malignancies as well as in congenital malformations. 21) Similarly, the p300 gene has recently been implicated in leukemia, and mutations in both alleles have been observed in gastric and colorectal carcinomas. 22) Muraoka et al. reported that loss of heterozygosity on chromosome 22q, which was observed mainly in the stage of progression of colorectal carcinoma, resulted in loss and missense mutations in the p300 gene in a colorectal carcinoma.
22) The factors that are involved in the low level expression of CBP protein in DLD-1 cells must be elucidated in future investigations.
In addition, we showed that an HDAC inhibitor, TSA, enhanced both basal and RA-induced bRARE activity in DLD-1 cells (Fig. 5) , which indicates that HDAC-associated chromatin remodeling may also have an important role in transcription of the RARb gene in cells. Consistent with our results, it has been reported that transcription of the RARb gene was observed by TSA treatment in estrogen receptornegative, RA-resistant breast cancer cells. 15, 23) Another epigenetic change that induces chromatin modifications could be DNA methylation, which represses transcription via a methyl CpG binding protein MeCP2, and recruitment of a Sin3A/HDAC corepressor complex. 24, 25) Hypermethylation of normally unmethylated CpG islands in the promoter region of RARb in DLD-1 has been recognized as a mechanism of poor expression of RARb. 26) Thus the DNA methylation inhibitor, 5-aza-2Ј-deoxycytidine (5-AZA-CdR) in combination with all-trans-RA produced a synergistic antineoplastic effect on DLD-1. 27) As in the case of colon cancer, treatment with 5-AZA-CdR partially reversed the DNA methylation state and restored RARb transcription in RA-resistant human breast cancer cells. 15, 24) Importantly, the combination of TSA and 5-AZA-CdR appeared to produce greater activation of the RARb gene in breast cancer cells, indicating that demethylation of the RARb promoter is not an absolute requirement for RARb reactivation. 15) Therefore the possibility of reinducing RARb activity in RA-resistant colon cancer cells, using chromatin-remodeling drugs such as HDAC inhibitors together with DNA methylase inhibitors, might have therapeutic implications for the treatment of colon cancer. 
